About US
Contact us
-
Pfizer prevails in first court test of Zoloft birth-defect claimsPfizer ($PFE) racked up an important win in the first trial over Zoloft's alleged links to birth defects. A St. Louis jury decided on Friday that the drug giant isn't liable for congenital abnormaliti2015/4/21
-
GSK yanks all doses of quadrivalent flu jab for potency problemsThis past season's flu vaccines posted one of the worst efficacy rates in recent memory. That's partly because the viral strains they contained weren't the ones that ended up circulating. But on top2015/4/21
-
Merck KGaA shareholders rewarded for hard work of turning company aroundMerck KGaAChairman Karl-Ludwig Kley is feeling pretty good about the hard work his company has accomplished in the last three years or so. A tough series of job cuts helped it exceed cost-cutting goal2015/4/20
-
BMS' PD-1 drug Opdivo continues on stellar trajectoryThe immuno-oncology drug Opdivo from Bristol-Myers Squibb ($BMY) continued on its charmed path today when the drugmaker cut short another trial for lung cancer because it had nailed its goal for overa2015/4/20
-
Sanofi expands PA vaccine facility to prepare for dengue launchSanofi ($SNY) plans to manufacture its highly anticipateddenguevaccine in a French facility built specifically for the product. ButSanofi Pasteur's vaccine operation in Swiftwater, PA, is also expandi2015/4/17
-
BMS, focused on immuno-oncology, turns Erbitux over to Eli LillyErbituxis one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb ($BMY) has sold it in the U.S. But Erbitux no longer fits in the sweet spot for Bristol-Myers whic2015/4/17
-
Pfizer's Ibrance shines in latest breast cancer studyPfizer ($PFE) won accelerated approval of Ibrance as a first-line breast cancer treatment in February. Now it says that data in a study of the drug as a second-line treatment was so good that it stopp2015/4/16
-
Gilead's hep C drugs make it king of the hill in U.S. drug salesThe U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences ($GILD), whose hep C2015/4/16
-
Record new drug sales give a mega-boost to U.S. drug spendingGiven the flood of numbers onhepatitis Ctreatment costs, it's no surprise that U.S. drug spending took a leap last year. Given the news on specialty drug prices, it's also no surprise that the biggest2015/4/15
-
Onglyza's label should flag heart failure risks, FDA panel saysAstraZeneca ($AZN) escaped the worst with anFDApanel vote on Onglyza. The agency's expert advisers almost unanimously backed the drug's cardiovascular safety. But the panel also recommended that the d2015/4/15